Literature DB >> 27887963

Animal models in the pharmacokinetic/pharmacodynamic evaluation of antimicrobial agents.

Miao Zhao1, Alexander J Lepak2, David R Andes3.   

Abstract

Animal infection models in the pharmacokinetic/pharmacodynamic (PK/PD) evaluation of antimicrobial therapy serve an important role in preclinical assessments of new antibiotics, dosing optimization for those that are clinically approved, and setting or confirming susceptibility breakpoints. The goal of animal model studies is to mimic the infectious diseases seen in humans to allow for robust PK/PD studies to find the optimal drug exposures that lead to therapeutic success. The PK/PD index and target drug exposures obtained in validated animal infection models are critical components in optimizing dosing regimen design in order to maximize efficacy while minimize the cost and duration of clinical trials. This review outlines the key components in animal infection models which have been used extensively in antibiotic discovery and development including PK/PD analyses. Copyright Â
© 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Animal model; Drug development; Pharmacodynamics; Pharmacokinetics

Mesh:

Substances:

Year:  2016        PMID: 27887963     DOI: 10.1016/j.bmc.2016.11.008

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  23 in total

1.  Pharmacodynamics of Tebipenem: New Options for Oral Treatment of Multidrug-Resistant Gram-Negative Infections.

Authors:  Laura McEntee; Adam Johnson; Nicola Farrington; Jennifer Unsworth; Aaron Dane; Akash Jain; Nicole Cotroneo; Ian Critchley; David Melnick; Thomas Parr; Paul G Ambrose; Shampa Das; William Hope
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

2.  Inhibition of Pseudomonas aeruginosa and Mycobacterium tuberculosis disulfide bond forming enzymes.

Authors:  Cristina Landeta; Laura McPartland; Ngoc Q Tran; Brian M Meehan; Yifan Zhang; Zaidi Tanweer; Shoko Wakabayashi; Jeremy Rock; Taehyun Kim; Deepak Balasubramanian; Rebecca Audette; Melody Toosky; Jessica Pinkham; Eric J Rubin; Stephen Lory; Gerald Pier; Dana Boyd; Jon Beckwith
Journal:  Mol Microbiol       Date:  2019-03-18       Impact factor: 3.501

3.  D-cycloserine increases the effectiveness of vancomycin against vancomycin-highly resistant Staphylococcus aureus.

Authors:  Fumiaki Tabuchi; Yasuhiko Matsumoto; Masaki Ishii; Keita Tatsuno; Mitsuhiro Okazaki; Tomoaki Sato; Kyoji Moriya; Kazuhisa Sekimizu
Journal:  J Antibiot (Tokyo)       Date:  2017-06-07       Impact factor: 2.649

4.  Generality of Post-Antimicrobial Treatment Persistence of Borrelia burgdorferi Strains N40 and B31 in Genetically Susceptible and Resistant Mouse Strains.

Authors:  Emir Hodzic; Denise M Imai; Edlin Escobar
Journal:  Infect Immun       Date:  2019-09-19       Impact factor: 3.441

5.  Transdermal delivery of gentamicin using dissolving microneedle arrays for potential treatment of neonatal sepsis.

Authors:  Patricia González-Vázquez; Eneko Larrañeta; Maelíosa T C McCrudden; Courtney Jarrahian; Annie Rein-Weston; Manjari Quintanar-Solares; Darin Zehrung; Helen McCarthy; Aaron J Courtenay; Ryan F Donnelly
Journal:  J Control Release       Date:  2017-07-25       Impact factor: 9.776

6.  Extrapolating Antifungal Animal Data to Humans - Is it reliable?

Authors:  Victoria M Stevens; Scott W Mueller; Paul M Reynolds; Robert MacLaren; Tyree H Kiser
Journal:  Curr Fungal Infect Rep       Date:  2020-01-16

7.  Efficacy of Telavancin in Comparison to Linezolid in a Porcine Model of Severe Methicillin-Resistant Staphylococcus aureus Pneumonia.

Authors:  D Battaglini; A Motos; G Li Bassi; H Yang; F Pagliara; M Yang; E Aguilera Xiol; A Meli; J Bobi; G Frigola; T Senussi; F Idone; C Travierso; C Chiurazzi; L Fernandez-Barat; M Rigol; J Ramirez; P Pelosi; D Chiumello; M Antonelli; D P Nicolau; J Bringue; A Artigas; L Guerrero; D Soy; A Torres
Journal:  Antimicrob Agents Chemother       Date:  2020-12-16       Impact factor: 5.191

Review 8.  Pharmacokinetics and pharmacodynamics in the treatment of cutaneous leishmaniasis - challenges and opportunities.

Authors:  Katrien Van Bocxlaer; Simon L Croft
Journal:  RSC Med Chem       Date:  2021-01-07

Review 9.  The Role of PK/PD Analysis in the Development and Evaluation of Antimicrobials.

Authors:  Alicia Rodríguez-Gascón; María Ángeles Solinís; Arantxa Isla
Journal:  Pharmaceutics       Date:  2021-06-03       Impact factor: 6.321

10.  Antibacterial Activity of a Promising Antibacterial Agent: 22-(4-(2-(4-Nitrophenyl-piperazin-1-yl)-acetyl)-piperazin-1-yl)-22-deoxypleuromutilin.

Authors:  Xiang-Yi Zuo; Hong Gao; Mei-Ling Gao; Zhen Jin; You-Zhi Tang
Journal:  Molecules       Date:  2021-06-08       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.